MAMaría Soledad Avendaño

María Soledad Avendaño

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


María Soledad Avendaño has a total of 95 co-authors. Here are the top co-authors by number of shared publications:

  • Mercedes Salaices

    Departamento de Farmacología, Universidad Autónoma de Madrid, 28029 Madrid, Spain

    9 shared publications
  • Ana Maria Briones

    Departamento de Farmacología, Facultad de Medicina, Universidad Autónoma de Madrid and Instituto de Investigación Hospital Universitario La Paz (IdiPaz) , 28029 Madrid

    5 shared publications
  • Maria Jesus Alonso

    Department of Basic Health Sciences, Universidad Rey Juan Carlos, Alcorcón, Spain

    5 shared publications
  • Manuel Tena-Sempere

    Ciber Fisiopatologia de la Obesidad y Nutricion, Instituto de Salud Carlos III, Madrid, Spain

    4 shared publications
  • Sonia Martínez-Revelles

    From the Departmento de Farmacología, Instituto de Investigación Hospital La Paz, Universidad Autónoma de Madrid, Spain (M.S.A., A.B.G.-R., M.G.-A., A.A., S.M.-R., M.S., A.M.B.).

    4 shared publications
  • Ana B. García-Redondo

    From the Departmento de Farmacología, Instituto de Investigación Hospital La Paz, Universidad Autónoma de Madrid, Spain (M.S.A., A.B.G.-R., M.G.-A., A.A., S.M.-R., M.S., A.M.B.).

    3 shared publications

Latest Publications

  • Open Access

    Kisspeptin treatment induces gonadotropic responses and rescues ovulation in a subset of preclinical models and women with polycystic ovary syndrome

    by A Romero-Ruiz, K Skorupskaite, F Gaytan, E Torres, C Perdices-Lopez, B M Mannaerts, S Qi, S Leon, M Manfredi-Lozano, C Lopez-Rodriguez, et al.

    Can kisspeptin treatment induce gonadotrophin responses and ovulation in preclinical models and anovulatory women with polycystic ovary syndrome (PCOS)? Kisspeptin administration in some anovulatory preclinical models and women with PCOS can stimulate reproductive hormone secretion and ovulation, albeit with incomplete efficacy. PCOS is a prevalent, heterogeneous endocrine disorder, characterized by ovulatory dysfunction, hyperandrogenism and deregulated gonadotrophin secretion, in need of improved therapeutic options. Kisspeptins (encoded by Kiss1) are master regulators of the reproductive axis, acting mainly at GnRH neurons, with kisspeptins being an essential drive for gonadotrophin-driven ovarian follicular maturation and ovulation. Altered Kiss1 expression has been found in rodent models of PCOS, although the eventual pathophysiological role of kisspeptins in PCOS remains unknown. Gonadotrophin and ovarian/ovulatory responses to kisspeptin-54 (KP-54) were evaluated in three preclinical models of PCOS, generated by androgen exposures at different developmental windows, and a pilot exploratory cohort of anovulatory women with PCOS. Three models of PCOS were generated by exposure of female rats to androgens at different periods of development: PNA (prenatal androgenization; N = 20), NeNA (neonatal androgenization; N = 20) and PWA (post-weaning androgenization; N = 20). At adulthood (postnatal day 100), rats were subjected to daily treatments with a bolus of KP-54 (100 μg/kg, s.c.) or vehicle for 11 days (N = 10 per model and treatment). On Days 1, 4, 7 and 11, LH and FSH responses were assessed at different time-points within 4 h after KP-54 injection, while ovarian responses, in terms of follicular maturation and ovulation, were measured at the end of the treatment. In addition, hormonal (gonadotrophin, estrogen and inhibin B) and ovulatory responses to repeated KP-54 administration, at doses of 6.4–12.8 nmol/kg, s.c. bd for 21 days, were evaluated in a pilot cohort of anovulatory women (N = 12) diagnosed with PCOS, according to the Rotterdam criteria. Deregulated reproductive indices were detected in all PCOS models: PNA, NeNA and PWA. Yet, anovulation was observed only in NeNA and PWA rats. However, while anovulatory NeNA rats displayed significant LH and FSH responses to KP-54 (P < 0.05), which rescued ovulation, PWA rats showed blunted LH secretion after repeated KP-54 injection and failed to ovulate. In women with PCOS, KP-54 resulted in a small rise in LH (P < 0.05), with an equivalent elevation in serum estradiol levels (P < 0.05). Two women showed growth of a dominant follicle with subsequent ovulation, one woman displayed follicle growth but not ovulation and desensitization was observed in another patient. No follicular response was detected in the other women. While three different preclinical PCOS models were used in order to capture the heterogeneity of clinical presentations of the syndrome, it must be noted that rat models recapitulate many but not all the features of this condition. Additionally, our pilot study was intended as proof of principle, and the number of participants is low, but the convergent findings in preclinical and clinical studies reinforce the validity of our conclusions. Our first-in-rodent and -human studies demonstrate that KP-54 administration in anovulatory preclinical models and women with PCOS can stimulate reproductive hormone secretion and ovulation, albeit with incomplete efficacy. As our rat models likely reflect the diversity of PCOS phenotypes, our results argue for the need of personalized management of anovulatory dysfunction in women with PCOS, some of whom may benefit from kisspeptin-based treatments. This work was supported by research agreements between Ferring Research Institute and the Universities of Cordoba and Edinburgh. K.S. was supported by the Wellcome Trust Scottish Translational Medicine and Therapeutics Initiative (STMTI). Some of this work was undertaken in the MRC Centre for Reproductive Health which is funded by the MRC Centre grant MR/N022556/1. M.T.-S. is a member of CIBER Fisiopatología de la Obesidad y Nutrición, which is an initiative of Instituto de Salud Carlos III. Dr Mannaerts is an employee of Ferring International PharmaScience Center (Copenhagen, Denmark), and Drs Qi, van Duin and Kohout are employees of the Ferring Research Institute (San Diego, USA). Dr Anderson and Dr Tena-Sempere were recipients of a grant support from the Ferring Research Institute, and Dr Anderson has undertaken consultancy work and received speaker fees outside this study from Merck, IBSA, Roche Diagnostics, NeRRe Therapeutics and Sojournix Inc. Dr Skorupskaite was supported by the Wellcome Trust through the Scottish Translational Medicine and Therapeutics Initiative 102419/Z/13/A. The other authors have no competing interest.


  • Open Access

    Deregulation of miR-324/KISS1/kisspeptin in early ectopic pregnancy: mechanistic findings with clinical and diagnostic implications

    by Antonio Romero-Ruiz, Maria S. Avendaño, Francisco Dominguez, Teresa Lozoya, Helena Molina-Abril, Susana Sangiao-Alvarellos, Marta Gurrea, Maribel Lara-Chica, Manuel Fernandez-Sanchez, Encarnación Torres-Jimenez, et al.


  • mPGES-1 (Microsomal Prostaglandin E Synthase-1) Mediates Vascular Dysfunction in Hypertension Through Oxidative Stress

    by María S. Avendaño, Ana B. García-Redondo, Guillermo Zalba, María González-Amor, Andrea Aguado, Sonia Martínez-Revelles, Luis M. Beltrán, Mercedes Camacho, Victoria Cachofeiro, María J. Alonso, et al.

    MPGES-1 (microsomal prostaglandin E synthase-1), the downstream enzyme responsible for PGE 2 (prostaglandin E 2 ) synthesis in inflammatory conditions and oxidative stress are increased in vessels from hypertensive animals. We evaluated the role of mPGES-1–derived PGE 2 in the vascular dysfunction and remodeling in hypertension and the possible contribution of oxidative stress. We used human peripheral blood mononuclear cells from asymptomatic patients, arteries from untreated and Ang II (angiotensin II)–infused mPGES-1 −/− and mPGES-1 +/+ mice, and vascular smooth muscle cells exposed to PGE 2 . In human cells, we found a positive correlation between mPGES-1 mRNA and carotid intima-media thickness ( r =0.637; P r =0.417; P 2 increased NADPH oxidase expression and activity and reduced mitochondrial membrane potential, effects that were abolished by antagonists of the PGE 2 receptors (EP), EP1 and EP3, and by JNK (c-Jun N-terminal kinase) and ERK1/2 (extracellular-signal–regulated kinases 1/2) inhibition. Deletion of mPGES-1 augmented vascular production of PGI 2 suggesting rediversion of the accumulated PGH 2 substrate. In conclusion, mPGES-1–derived PGE 2 is involved in vascular remodeling, stiffness, and endothelial dysfunction in hypertension likely through an increase of oxidative stress produced by NADPH oxidase and mitochondria.


  • Open Access

    Lysyl Oxidase Induces Vascular Oxidative Stress and Contributes to Arterial Stiffness and Abnormal Elastin Structure in Hypertension: Role of p38MAPK

    by Sonia Martínez-Revelles, Ana B. García-Redondo, María S. Avendaño, Saray Varona, Teresa Palao, Mar Orriols, Fernanda R. Roque, Ana Fortuño, Rhian M. Touyz, Jose Martínez-González, et al.

    Aims: Vascular stiffness, structural elastin abnormalities, and increased oxidative stress are hallmarks of hypertension. Lysyl oxidase (LOX) is an elastin crosslinking enzyme that produces H 2 O 2 as a by-product. We addressed the interplay between LOX, oxidative stress, vessel stiffness, and elastin. Results: Angiotensin II (Ang II)-infused hypertensive mice and spontaneously hypertensive rats (SHR) showed increased vascular LOX expression and stiffness and an abnormal elastin structure. Mice over-expressing LOX in vascular smooth muscle cells (TgLOX) exhibited similar mechanical and elastin alterations to those of hypertensive models. LOX inhibition with β-aminopropionitrile (BAPN) attenuated mechanical and elastin alterations in TgLOX mice, Ang II-infused mice, and SHR. Arteries from TgLOX mice, Ang II-infused mice, and/or SHR exhibited increased vascular H 2 O 2 and O 2 .− levels, NADPH oxidase activity, and/or mitochondrial dysfunction. BAPN prevented the higher oxidative stress in hypertensive models. Treatment of TgLOX and Ang II-infused mice and SHR with the mitochondrial-targeted superoxide dismutase mimetic mito-TEMPO, the antioxidant apocynin, or the H 2 O 2 scavenger polyethylene glycol-conjugated catalase (PEG-catalase) reduced oxidative stress, vascular stiffness, and elastin alterations. Vascular p38 mitogen-activated protein kinase (p38MAPK) activation was increased in Ang II-infused and TgLOX mice and this effect was prevented by BAPN, mito-TEMPO, or PEG-catalase. SB203580, the p38MAPK inhibitor, normalized vessel stiffness and elastin structure in TgLOX mice. Innovation: We identify LOX as a novel source of vascular reactive oxygen species and a new pathway involved in vascular stiffness and elastin remodeling in hypertension. Conclusion: LOX up-regulation is associated with enhanced oxidative stress that promotes p38MAPK activation, elastin structural alterations, and vascular stiffness. This pathway contributes to vascular abnormalities in hypertension. Antioxid. Redox Signal. 27, 379–397.


  • Disentangling puberty: novel neuroendocrine pathways and mechanisms for the control of mammalian puberty

    by M S Avendaño, M J Vazquez, M Tena-Sempere

    Puberty is a complex developmental event, controlled by sophisticated regulatory networks that integrate peripheral and internal cues and impinge at the brain centers driving the reproductive axis. The tempo of puberty is genetically determined but is also sensitive to numerous modifiers, from metabolic and sex steroid signals to environmental factors. Recent epidemiological evidence suggests that the onset of puberty is advancing in humans, through as yet unknown mechanisms. In fact, while much knowledge has been gleaned recently on the mechanisms responsible for the control of mammalian puberty, fundamental questions regarding the intimate molecular and neuroendocrine pathways responsible for the precise timing of puberty and its deviations remain unsolved. By combining data from suitable model species and humans, we aim to provide a comprehensive summary of our current understanding of the neuroendocrine mechanisms governing puberty, with particular focus on its central regulatory pathways, underlying molecular basis and mechanisms for metabolic control. A comprehensive MEDLINE search of articles published mostly from 2003 to 2017 has been carried out. Data from cellular and animal models (including our own results) as well as clinical studies focusing on the pathophysiology of puberty in mammals were considered and cross-referenced with terms related with central neuroendocrine mechanisms, metabolic control and epigenetic/miRNA regulation. Studies conducted during the last decade have revealed the essential role of novel central neuroendocrine pathways in the control of puberty, with a prominent role of kisspeptins in the precise regulation of the pubertal activation of GnRH neurosecretory activity. In addition, different transmitters, including neurokinin-B (NKB) and, possibly, melanocortins, have been shown to interplay with kisspeptins in tuning puberty onset. Alike, recent studies have documented the role of epigenetic mechanisms, involving mainly modulation of repressors that target kisspeptins and NKB pathways, as well as microRNAs and the related binding protein, Lin28B, in the central control of puberty. These novel pathways provide the molecular and neuroendocrine basis for the modulation of puberty by different endogenous and environmental cues, including nutritional and metabolic factors, such as leptin, ghrelin and insulin, which are known to play an important role in pubertal timing. Despite recent advancements, our understanding of the basis of mammalian puberty remains incomplete. Complete elucidation of the novel neuropeptidergic and molecular mechanisms summarized in this review will not only expand our knowledge of the intimate mechanisms responsible for puberty onset in humans, but might also provide new tools and targets for better prevention and management of pubertal deviations in the clinical setting.


  • Open Access

    Development and validation of a method for precise dating of female puberty in laboratory rodents: The puberty ovarian maturation score (Pub-Score)

    by Francisco Gaytan, Concepción Morales, Silvia Leon, Violeta Heras, Alexia Barroso, Maria S. Avendaño, Maria J. Vazquez, Juan M. Castellano, Juan Roa, Manuel Tena-Sempere

    Puberty is a key developmental event whose primary regulatory mechanisms remain poorly understood. Precise dating of puberty is crucial for experimental (preclinical) studies on its complex neuroendocrine controlling networks. In female laboratory rodents, external signs of puberty, such as vaginal opening (VO) and epithelial cell cornification (i.e., first vaginal estrus, FE), are indirectly related to the maturational state of the ovary and first ovulation, which is the unequivocal marker of puberty. Whereas in rats, VO and FE are almost simultaneous with the first ovulation, these events are not so closely associated in mice. Moreover, external signs of puberty can be uncoupled with first ovulation in both species under certain experimental conditions. We propose herein the Pubertal Ovarian Maturation Score (Pub-score), as novel, reliable method to assess peripubertal ovarian maturation in rats and mice. This method is founded on histological evaluation of pre-pubertal ovarian maturation, based on antral follicle development, and the precise timing of first ovulation, by retrospective dating of maturational and regressive changes in corpora lutea. This approach allows exact timing of puberty within a time-window of at least two weeks after VO in both species, thus facilitating the identification and precise dating of advanced or delayed puberty under various experimental conditions.


  • Role of COX‐2‐derived PGE2 on vascular stiffness and function in hypertension

    by M S Avendaño, S Martínez‐Revelles, A Aguado, M R Simões, M González‐Amor, R Palacios, P Guillem‐Llobat, D V Vassallo, L Vila, J García‐Puig, et al.

    Background and Purpose: Prostanoids derived from COX‐2 and EP receptors are involved in vascular remodelling in different cardiovascular pathologies. This study evaluates the contribution of COX‐2 and EP1 receptors to vascular remodelling and function in hypertension.Experimental Approach: Spontaneously hypertensive rats (SHR) and angiotensin II (AngII)‐infused (1.44 mg·kg−1·day−1, 2 weeks) mice were treated with the COX‐2 inhibitor celecoxib (25 mg·kg−1·day−1 i.p) or with the EP1 receptor antagonist SC19220 (10 mg·kg−1·day−1 i.p.). COX‐2−/− mice with or without AngII infusion were also used.Key Results: Celecoxib and SC19220 treatment did not modify the altered lumen diameter and wall : lumen ratio in mesenteric resistance arteries from SHR‐infused and/or AngII‐infused animals. However, both treatments and COX‐2 deficiency decreased the augmented vascular stiffness in vessels from hypertensive animals. This was accompanied by diminished vascular collagen deposition, normalization of altered elastin structure and decreased connective tissue growth factor and plasminogen activator inhibitor‐1 gene expression. COX‐2 deficiency and SC19220 treatment diminished the increased vasoconstrictor responses and endothelial dysfunction induced by AngII infusion. Hypertensive animals showed increased mPGES‐1 expression and PGE2 production in vascular tissue, normalized by celecoxib. Celecoxib treatment also decreased AngII‐induced macrophage infiltration and TNF‐α expression. Macrophage conditioned media (MCM) increased COX‐2 and collagen type I expression in vascular smooth muscle cells; the latter was reduced by celecoxib treatment.Conclusions and Implications: COX‐2 and EP1 receptors participate in the increased extracellular matrix deposition and vascular stiffness, the impaired vascular function and inflammation in hypertension. Targeting PGE2 receptors might have benefits in hypertension‐associated vascular damage.


  • Cerebrovascular endothelial dysfunction induced by mercury exposure at low concentrations

    by Giulia Alessandra Wiggers, Lorena Barros Furieri, Ana María Briones, María Soledad Avendaño, Franck Maciel Peçanha, Dalton Valentim Vassallo, Mercedes Salaices, María Jesús Alonso


  • HuR mediates the synergistic effects of angiotensin II and IL‐1β on vascular COX‐2 expression and cell migration

    by A Aguado, C Rodríguez, S Martínez‐Revelles, M S Avendaño, O Zhenyukh, M Orriols, J Martínez‐González, M J Alonso, A M Briones, D A Dixon, et al.

    Background and Purpose: Angiotensin II (AngII) and IL‐1β are involved in cardiovascular diseases through the induction of inflammatory pathways. HuR is an adenylate‐ and uridylate‐rich element (ARE)‐binding protein involved in the mRNA stabilization of many genes. This study investigated the contribution of HuR to the increased expression of COX‐2 induced by AngII and IL‐1β and its consequences on VSMC migration and remodelling.Experimental Approach: Rat and human VSMCs were stimulated with AngII (0.1 μM) and/or IL‐1β (10 ng·mL−1). Mice were infused with AngII or subjected to carotid artery ligation. mRNA and protein levels were assayed by quantitative PCR, Western blot, immunohistochemistry and immunofluorescence. Cell migration was measured by wound healing and transwell assays.Key Results: In VSMCs, AngII potentiated COX‐2 and tenascin‐C expressions and cell migration induced by IL‐1β. This effect of AngII on IL‐1β‐induced COX‐2 expression was accompanied by increased COX‐2 3′ untranslated region reporter activity and mRNA stability, mediated through cytoplasmic HuR translocation and COX‐2 mRNA binding. These effects were blocked by ERK1/2 and HuR inhibitors. VSMC migration was reduced by blockade of ERK1/2, HuR, COX‐2, TXAS, TP and EP receptors. HuR, COX‐2, mPGES‐1 and TXAS expressions were increased in AngII‐infused mouse aortas and in carotid‐ligated arteries. AngII‐induced tenascin‐C expression and vascular remodelling were abolished by celecoxib and by mPGES‐1 deletion.Conclusions and Implications: The synergistic induction of COX‐2 by AngII and IL‐1β in VSMCs involves HuR through an ERK1/2‐dependent mechanism. The HuR/COX‐2 axis participates in cell migration and vascular damage. HuR might be a novel target to modulate vascular remodelling.


  • Increased Nitric Oxide Bioavailability in Adult GRK2 Hemizygous Mice Protects Against Angiotensin II–Induced Hypertension

    by María S. Avendaño, Elisa Lucas, María Jurado-Pueyo, Sonia Martínez-Revelles, Rocío Vila-Bedmar, Federico Mayor, Mercedes Salaices, Ana M. Briones, Cristina Murga

    G protein–coupled receptor kinase 2 (GRK2) is a ubiquitous serine/threonine protein kinase able to phosphorylate and desensitize the active form of several G protein–coupled receptors. Given the lack of selective inhibitors for GRK2, we investigated the effects elicited by GRK2 inhibition in vascular responses using global adult hemizygous mice (GRK2 +/− ). The vasodilator responses to acetylcholine or isoproterenol were increased in aortas and mesenteric resistance arteries from GRK2 +/− mice compared with wild-type (WT) littermates. After angiotensin II (AngII) infusion, GRK2 +/− mice were partially protected against hypertension, vascular remodeling, and mechanical alterations, even when resting basal blood pressures were not significantly different. AngII infusion also (1) increased GRK2 levels in WT but not in GRK2 +/− vessels; (2) increased vasoconstrictor responses to phenylephrine in WT but not in GRK2 +/− mice; and (3) decreased vasodilator responses to acetylcholine and vascular pAkt and eNOS levels more in WT than in GRK2 +/− animals. Vascular NO production and the modulation of vasoconstrictor responses by endothelial-derived NO remained enhanced in GRK2 +/− mice infused with AngII. Thus, GRK2 +/− mice are resistant to the development of vascular remodeling and mechanical alterations, endothelial dysfunction, increased vasoconstrictor responses, and hypertension induced by AngII at least partially through the preservation of NO bioavailability. In conclusion, our results describe an important role for GRK2 in systemic hypertension and further establish that an inhibition of GRK2 could be a beneficial treatment for this condition.